WS #16686

The dominant market narrative has shifted from geopolitical crisis to a sharp de-escalation of Middle East tensions. Following the previous cycle's high-impact signal that Iran signaled a Hormuz reopening, crude prices have plunged 7%, effectively neutralizing the energy supply shock thesis. This macro relief has triggered a rotation into risk assets, with US equity futures advancing and technology shares leading the recovery. The prevailing thesis of 'escalation' is now being challenged by this concrete pricing signal, dampening the bearish impact on airlines and consumer discretionary while providing a tailwind for the AI trade that was bruised earlier in the week. In corporate developments, the M&A and capital markets landscape remains active but distinct from the macro pivot. Marvell's $115B all-stock acquisition of Lumentum stands as a massive consolidation play in the photonics/AI infrastructure space, signaling aggressive capex cycles. Meanwhile, Google's €6 billion Euro bond issuance highlights the continued appetite for European capital by US tech giants to fund AI infrastructure. On the biotech front, Novartis' Phase III failure for pelacarsen provides a specific negative signal for the lipid-lowering sector, contrasting with the broader market's risk-on mood. Secondary activity includes a tender offer for EVgo by LS Power, reflecting the ongoing consolidation in the EV charging infrastructure sector, and a series of smaller M&A completions in regional banking and asset management. The market is currently in a 'waiting room' mode ahead of major earnings from Apple and Palantir, with the macro backdrop of falling oil prices providing a supportive floor for the morning session.